Balaxi Pharmaceuticals, an IPR-driven firm with 610 product registrations, saw Q1FY26 net sales rise 8% to ₹70.74 crore, with ₹0.29 crore net profit. FY25 annual net sales grew 22% to ₹293 crore. Net profit surged 1,350% to ₹25 crore in FY25 from a ₹2 crore loss in FY24. The company's PE is 14x with market cap of over ₹250 crore.